Dihydroergotamine mesilate inhalation - Allergan

Drug Profile

Dihydroergotamine mesilate inhalation - Allergan

Alternative Names: DHE-inhalation - MAP; Levadex®; MAP 0004; SEMPRANA

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MAP Pharmaceuticals
  • Developer Allergan
  • Class Antimigraines; Ergotamines; Mesylates; Small molecules
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Preregistration Migraine

Most Recent Events

  • 22 Feb 2016 Allergan announces intention to submit NDA to US FDA in 2016
  • 29 Jun 2015 Dihydroergotamine mesilate inhalation is still in Preregistration for Migraine (in adults) in USA
  • 31 Mar 2015 Dihydroergotamine mesilate inhalation is still in clinical development for Migraine (in adolescents)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top